行情

KPTI

KPTI

Karyopharm
NASDAQ

实时行情|Nasdaq Last Sale

15.44
-0.16
-1.03%
已收盘, 17:42 11/18 EST
开盘
15.60
昨收
15.60
最高
15.80
最低
15.33
成交量
114.64万
成交额
--
52周最高
15.80
52周最低
3.920
市值
9.69亿
市盈率(TTM)
-4.5103
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KPTI 新闻

  • 沪指低开高走 鲍威尔同特朗普及美财长会晤
  • 新浪财经.38分钟前
  • 日本众院通过日美贸易协定 执政党力争12月获批
  • 中国新闻网.1小时前
  • 汇丰:英镑前路难以预测 飙升与崩跌皆有可能
  • 新浪财经综合.1小时前
  • 英国大选进入白热化阶段 约翰逊“四问”科尔宾
  • 中国新闻网.2小时前

更多

所属板块

生物技术和医学研究
+0.31%
制药与医学研究
+0.13%

热门股票

名称
价格
涨跌幅

KPTI 简况

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
展开

Webull提供Karyopharm Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。